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Some trace elements are altered with chronic kidney disease. Sele-
nium, zinc, and manganese tend to be wasted, and there is growing 
evidence that selenium deficiency is associated with mortality 
on dialysis. Other trace elements accumulate, such as chromium, 
cobalt, lead, molybdenum, and vanadium. The highest chromium 
levels are found in dialysis patients. The dialysis modality may 
further affect these levels, especially in hemodialysis patients, 
where even small contaminations in the dialysis feed water may 
lead to a concentration gradient that increases the concentration 
of certain trace elements. Chromium levels in peritoneal dialysis 
(PD) patients have been understudied. A single cross-sectional 
study found substantially higher chromium levels in PD patients. 
In that study, the chromium concentration in the spent dialysate 
decreased substantially, suggesting that PD fluid could be a source 
of chromium. Chromium-lactate complexes may have been formed, 
which are easily absorbed. In our center, we observed a decrease 
in chromium level when using physiological PD fluids. This review 
discusses the potential mechanisms and raises the question of 
whether this accumulation of chromium is unlikely to be associated 
with a beneficial outcome. 
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Chromium (Cr, atomic number 24) is well known as an addi-tive for steel alloys to create shiny metals and to prevent 
rusting. Metallic Cr does not occur in nature but is found in 
compounds, in a variety of valence states (1–2). Sources of 
exposure in humans include air, food, and water, with food 
and especially water being the main sources (2,3). Chromium 
concentrations in drinking water may be highly variable (4). 
Hexavalent Cr easily enters cells through facilitated uptake, 
and its reduction from Cr (VI) to Cr (III) creates free radicals 
(2). It is distributed to, and accumulated by, the erythrocyte 
while the highest concentrations of Cr are found in the 
kidney and liver. Chromium is highly protein-bound and is 
slowly excreted via the kidneys, by tubular secretion (4). 
Chromium is carcinogenic, as inhalation has been shown to 
cause lung cancer in humans, and exposure has been shown 
to cause tumors in the stomach, intestinal tract, and lung in 
animals (2). Depending on the route of exposure, trivalent 
and hexavalent Cr are also associated with gastrointestinal, 
immunological, hematological (such as anemia), reproductive, 
and developmental potentially devastating effects (4). While 
accumulation of Cr occurs in earlier states of chronic kidney 
disease (CKD) (4), Tonelli et al. have recently reported that Cr 
accumulates substantially in hemodialysis (HD) patients (5,6). 
This association was confirmed by measuring trace elements 
in the hair of adult HD patients (7). Chromium also accumu-
lates substantially in bone of dialysis patients (8). Data from 
peritoneal dialysis (PD) patients have been scant. 
In that context we are delighted to see a recent study of 
169 chronic dialysis patients from 3 Israeli centers in this 
edition of Peritoneal Dialysis International, which included 
21 PD patients. The median (interquartile range) serum Cr 
level was significantly higher in patients treated with PD 
than in patients treated with HD: 5.00 (3.24 – 6.15) versus 
1.83 (1.29 – 2.45) μg/L, p < 0.001. The association with PD 
became even stronger when using a multivariate regression 
model, with an odds ratio (OR) of 11.87 (95% confidence 
interval [CI] 2.85 – 49.52, p = 0.001). These findings remained 
significant after adjusting for age, gender, diabetes status, 
smoking, dialysis vintage, use of diuretics, and residual renal 
function (9). As all the patients came from the same area and 
had the same access to municipal drinking water, the authors 
did not adjust for the water Cr content (also assumed that 
mains rather than purchased bottled water was the main source 
of hydration). They checked the HD water for Cr and it was 
found to be below the American Association for Advancement 
of Medical Instrumentation (AAMI) standards. A particular 
strength of the study is the additional measurement of Cr in 
fresh and spent PD solutions, though only in 5 of the patients. 
Perhaps the most striking finding was the fact that the Cr 
concentration in the PD solutions decreased with treatment 
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(1.23 [0.76 – 1.45] μg/L in fresh and 0.25 [0.22 – 0.44] μg/L 
in spent solution), suggesting that PD fluid per se is a potential 
source for Cr. As elegantly discussed by the authors, Cr forms a 
Cr-lactate complex which is easily absorbed. It is unclear if more 
physiologic PD solutions such as Physioneal (Baxter Healthcare 
Corporation, Deerfield, IL, USA) or BicaVera (Fresenius Medical 
Care, Bad Homburg, Germany), in which lactate exposure is 
reduced/absent, would be more favorable from the point of 
view of Cr presentation for peritoneal absorption. One of the 
major limitations of the study is its lack of water and food Cr 
content assessment. The study also did not correlate data such 
as erythrocyte stimulating agent needs with Cr levels or any 
of the multiple side effects listed below. The authors conclude 
that the study adds to the present knowledge by demonstrating 
that Cr concentrations are higher in PD patients, and the results 
of the 5 patients suggests that the PD fluid was a significant 
source of Cr. The authors call for more longitudinal studies and 
indeed the measurement of exposure at a single time point 
does not allow the time/exposure element of the risk to be 
appreciated. The cross-sectional nature of this assessment also 
means that batch contamination of PD fluid (all supplied from 
a single facility) cannot be ruled out, injecting a little caution 
into interpretation of these data necessarily being indicative 
of innate differences between dialysis modalities. 
For studies measuring metal ion levels such as Cr, an 
important consideration is the valency (electron charge) of 
these ions. This is especially important with Cr, since it is well 
established that the Cr (VI) ion can easily enter cells and is 
associated with oxidative stress due to the reduction to Cr (III) 
in vivo (10). In contrast, the more commonly found Cr (III) 
ion is much less dangerous or may actually be beneficial 
(10). Chromium (VI) ion is more carcinogenic and cytotoxic 
than the Cr (III) ion (10). It is also unclear what Cr levels 
are safe. Most laboratories also do not test the Cr valency. 
In fact, chromium lactate is used in nutritional supplements 
as a source of chromium (11). In some long-term studies, 
investigators assume that Cr (VI) is reduced immediately to 
Cr (III), since this happens rapidly ex vivo, but this remains 
unproven. The study by Feldman et al. (10) did not measure the 
valency of Cr. 
It is also unclear whether these high Cr levels are harm-
ful. With oral exposure, Cr has been linked to the following, 
although there is little or no information about the valency 
(4,12): 
•		 Death	and,	 at	 lethal	 doses,	 respiratory	 effects	 such	as	
pleural ef fusion, pulmonary edema, bronchitis, and 
bronchopneumonia. 
•		 Cardiovascular	effects	such	as	cardiopulmonary	arrest,	and	
a drop in cardiac output, heart rate, and blood pressure. 
•		 Lung	cancer.
•		 Gastrointestinal	 effects	 from	Cr	 in	drinking	water	 such	
as oral ulcer, diarrhea, abdominal pain, indigestion, and 
vomiting. 
•		 Musculoskeletal	effects	such	as	rhabdomyolysis.	
•		 Hematological	effects	including	leukocytosis	and	immature	
neutrophils. 
•		 Hepatic	effects	such	as	the	development	of	jaundice,	and	
increased bilirubin, serum lactic dehydrogenase, alanine and 
aspartate aminotransferase, and γ-glutamyl transferase. 
•		 Direct	 renal	 effects	 such	as	 renal	 failure	 characterized	
by proteinuria, hematuria and anuria, necrosis of renal 
tubules, oliguria, and destruction of the tubular epithelium 
of the kidneys. 
•		 Chromium	supplementation	has	also	been	associated	with	
weight loss. 
Many, but not all of these Cr-related issues, are observed 
in renal patients. Associations also do not infer causality. In 
Tonelli’s study, death and cardiovascular risk were associated 
with essential trace element deficiencies, but not with Cr eleva-
tion (5,6). Nonetheless, this accumulation of Cr is unlikely to 
elicit a beneficial adaptive response. What should be done 
about his accumulation of Cr in PD patients? Based on the 
data provided, absorption of Cr from the dialysate clearly is a 
possibility. If so, we need to compare the findings with those 
in patients who are being treated with physiologic solutions. 
If Cr concentrations do not decrease in the spent fluid, this 
may be a powerful argument for the use of these solutions. 
In 1 of our patients on long-term PD (13) we noticed a slow 
steady decline of her Cr levels after converting her from HD to 
PD exclusively using biocompatible bicarbonate-containing 
low-lactate PD solutions (Figure 1). Concurrently, her lactate 
dehydrogenase (LD) gradually dropped from 253 U/L to 216 U/L 
(normal < 300 U/L) and the alkaline phosphatase dropped from 
405 U/L to 251 U/L (normal range 129 – 417 U/L). Clearly this 
is anecdotal, but it is highly consistent with the above concepts 
of the pathophysiology of Cr accumulation in PD patients.
CONCLUSIONS
We congratulate Leonid Feldman and the team on their 
study and hope to soon learn more about the impact of 
elevated Cr levels in CKD, especially in PD patients. As Tonelli 
et al. (5) have clearly shown, trace element derangements 
in dialysis patients affect outcomes, and perhaps it is prime 
time to start monitoring these in our dialysis patients. We also 
Figure 1 — Chromium levels in a child who was converted from HD to 
PD using high-dose CCPD with Physioneal. HD = hemodialysis; PD = 
peritoneal dialysis; CCPD = continuous cycling PD.
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need to establish safe levels in order to assess toxicity. This 
could potentially be done by linking cancer data of PD and HD 
patients to levels.
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